Weifa
| Company type | Allmennaksjeselskap |
|---|---|
| OSE: WEIFA | |
| Industry | Pharmaceutical |
| Founded | 1940 |
| Headquarters | Oslo, Norway |
| Revenue | 500mill NOK (2012) |
Number of employees | 99 |
| Website | www.weifa.no |
Weifa[1] is a Norwegian pharmaceutical company headquartered in Oslo with production facilities in Kragerø.
Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.
History
[edit]Weifa was founded by pharmacist Olaf Weider in 1940.[2]
Therapeutic areas
[edit]Weifa focuses on three therapeutic areas:
- Pain management
- Diabetes management
- Food supplements
Products
[edit]- bra!: Evening primrose oil.
- Bronkyl: Expectorant effervescent tablet.[3]
- Dexyl: Nasal spray.[4]
- Fanalgin: Pain reliever and fever reducer with an addition of caffeine.[5]
- Ferromax: Iron supplement.[6]
- Fluormax: Fluorine supplements.[7]
- Ibux: A brand name for ibuprofen.
- Ibux Gel: A gel version of Ibux.[8]
- Nazamér: Salt water spray.[9]
- Nazaren: Salt water nasal spray.[10]
- Paracet: A brand name for paracetamol.[11]
- Paracetduo: Similar to Paracet with the addition of caffeine for increased pain relief.[12]
- Proxan: Brand name for naproxen.[13]
- Pyrivir: Relieves symptoms of cold sores.[14]
- Samin: Symptom relief in patients with Osteoarthritis.
- Tigerbalsam: Heat rub.[15]
- Tussin: Cough medicine.[16]
- Weifa-C Nypeekstrakt: Vitamin C from rose hip extract.
- Weifa C-vitamin brusetabletter: Vitamin C effervescent tablets.
- Weifa Kalsium: Calcium supplements.
Active ingredients
[edit]- Codeine: Used in pain relievers and cough medicine.[17]
- Metformin: Used in first-line treatment of diabetes mellitus type 2.[18]
- Pholcodine: Used in cough medicine.[17]
Development
[edit]With a total of over 99 employees, Weifa is today generating an annual turnover of approximately €40 million (35% of the turnover is achieved internationally). Weifa bases its development on 3 criteria:
- International expansion
- Expertise in pharmaceuticals and fine chemicals
- Partnership agreements
Norway
[edit]Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.
Export
[edit]Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.
References
[edit]- ^ "Home". weifa.com.
- ^ "Kjøper Weifa for 1,17 milliarder". Dagens Næringsliv. 17 June 2014. Archived from the original on 9 October 2014.
- ^ "Bronkyl". Felleskatalogen. Archived from the original on 21 September 2014.
- ^ "Dexyl". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Fanalgin". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Ferromax". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Fluormax". Weifa. Archived from the original on 10 October 2014.
- ^ "Ibux Gel". Legemiddelsiden.no. Archived from the original on 8 October 2014.
- ^ "Nazamér". Weifa. Archived from the original on 27 August 2014.
- ^ "Nazaren". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Paracet". Felleskatalogen. Archived from the original on 24 August 2014.
- ^ "Paracetduo". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Proxan". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ "Pyrivir". Weifa. Archived from the original on 27 August 2014.
- ^ "Tigerbalsam". Weifa. Archived from the original on 26 August 2014.
- ^ "Tussin". Felleskatalogen. Archived from the original on 8 October 2014.
- ^ a b "Weifa - Opioids". Weifa. Archived from the original on 10 October 2014.
- ^ "Weifa - Metformin". Weifa. Archived from the original on 10 October 2014.
